Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.
2.
3.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
4.

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Russo EB, Guy GW, Robson PJ.

Chem Biodivers. 2007 Aug;4(8):1729-43. Review.

PMID:
17712817
5.

Combined cannabinoid therapy via an oromucosal spray.

Perez J.

Drugs Today (Barc). 2006 Aug;42(8):495-503. Review.

PMID:
16969427
6.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
7.
8.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
9.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

Moreno Torres I, Sanchez AJ, Garcia-Merino A.

Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.

PMID:
25331416
10.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
11.

Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.

Meuth SG, Vila C, Dechant KL.

Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11. Review.

PMID:
26166264
12.

Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?

Wade D.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):9-14. doi: 10.1586/ern.12.12. Review.

PMID:
22509986
13.

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.

Smith PF.

Expert Rev Neurother. 2007 Sep;7(9):1157-63. Review.

PMID:
17868014
14.

[Marihuana and cannobinoids as medicaments].

Tkaczyk M, Florek E, Piekoszewski W.

Przegl Lek. 2012;69(10):1095-7. Review. Polish.

PMID:
23421098
15.

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Oreja-Guevara C.

Rev Neurol. 2012 Oct 1;55(7):421-30. Review. Spanish.

16.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
17.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Epub 2012 Sep 7. Review.

PMID:
22954177
18.

Pharmacological management of pain in patients with multiple sclerosis.

Solaro C, Messmer Uccelli M.

Drugs. 2010 Jul 9;70(10):1245-54. doi: 10.2165/11537930-000000000-00000. Review.

PMID:
20568832
19.

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.

García-Merino A.

Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Review.

PMID:
23369054
20.

Towards cannabis and cannabinoid treatment of multiple sclerosis.

Croxford JL, Miller SD.

Drugs Today (Barc). 2004 Aug;40(8):663-76. Review.

PMID:
15510238
Items per page

Supplemental Content

Write to the Help Desk